Anixa Biosciences, MolGenie announce SARS-CoV-2 protease inhibitor

By The Science Advisory Board staff writers

January 25, 2022 -- Anixa Biosciences and its partner MolGenie have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting the main protease (Mpro) of the SARS-CoV-2 virus.

Nirmatrelvir is the main component of Pfizer's Paxlovid, which was recently authorized to treat COVID-19. Paxlovid also includes ritonavir, which is an HIV drug. Since the crystal structure of Mpro of SARS-CoV-2 was published, Anixa has worked with MolGenie to identify compounds that could inhibit this enzyme. Notably, the program is not reliant on targeting the SARS-CoV-2 spike protein, the firms said.

Recently identified variants, like delta and omicron, are characterized by mutations in the spike protein, but Mpro is largely conserved across all variants. Therefore, Anixa said it expects its compounds will be effective against all the currently known variants.

MolGenie is using and developing compound design technologies aiming at druglike and selective small molecules that exhibit a clear structure-activity relationship and have the promise of good tolerability and oral bioavailability. Anixa is a publicly traded biotechnology company developing a number of programs addressing cancer and infectious diseases.

Copyright © 2022
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here